New technique shields healthy liver during cancer radiation
NCT ID NCT06229080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a method to protect healthy liver tissue during Yttrium-90 radioembolization, a radiation treatment for liver cancer. Doctors injected short-acting gelatin particles into arteries supplying non-cancerous liver areas to temporarily block blood flow. The goal was to reduce radiation damage to healthy tissue. Twenty adults with primary or metastatic liver cancer participated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gelatin sponge particles (NexGel)
What this could lead to
If successful, this technique could help preserve healthy liver function during radiation treatment for liver cancer, potentially reducing side effects.
What could go wrong
This is a small, early-stage study with only 20 participants and no control group. The approach may not improve outcomes or could cause unexpected complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER (PRIMARY AND METASTATIC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea